GSK secures FDA breakthrough therapy designation for GSK5764227 in lung cancer treatment
GSK plc (LSE/NYSE: GSK) has announced a significant milestone in its oncology program, with the US Food and Drug Administration (FDA) granting Breakthrough Therapy Designation ... Read More
Brii Biosciences receives breakthrough therapy designations for HBV treatments
Brii Biosciences Limited, a biotechnology company developing therapies for diseases with high unmet need, announced that the Center for Drug Evaluation (CDE) of the National ... Read More
FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer
Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority ... Read More